Addressing COVID-19 Barriers to Clinical Trial Enrollment and Implementation in the PHARM-DC Study. (17th December 2021)

• Record Type: Journal Article
• Authors: Pevnick, Joshua; Keller, Michelle; Kennelty, Korey; Ko, Michelle; Murry, Logan; Nguyen, An; Henreid, Andrew; Schnipper, Jeffrey
• Is Part Of: Innovation in aging. Volume 5(2021)Supplement 1
• Page Start: 103
• Page End: 103
• Publication Date: 2021-12-17
• Subjects: Aging -- Periodicals; Gerontology -- Periodicals; 612.67
• DOI: 10.1093/geroni/igab046.393
• Languages: English
• ISSNs: 2399-5300

Abstract

Abstract: Recent hospitalization puts older adults at higher risk of experiencing adverse drug events (ADEs) that are a common cause of hospital readmission. Yet, most ADEs are preventable. The PHARMacist Discharge Care (PHARM-DC) study is a multi-site randomized controlled trial that seeks to evaluate the effect of pharmacist-led peri- and post-discharge interventions on 30-day hospital readmissions among older adults taking ≥10 medications or ≥3 high-risk medications. The PHARM-DC intervention includes pharmacist-led patient counseling, medication reconciliation at discharge, and a follow-up phone call post-discharge. We will highlight study protocol adaptations undertaken during the COVID-19 pandemic to address challenges to enrollment and to minimize risk of COVID-19 exposure for study participants and research personnel. Additionally, we will share insights from focus groups and semi-structured interviews with pharmacist interventionists and pharmacy leaders on barriers and facilitators to implementation due to the pandemic and strategies for future clinical trials to overcome barriers.